OCGN ▲ +4.5% - Ocugen, Inc. $OCGN Ocugen: Signs OCU400 Gene Therapy Licensing Deal Worth Up to $259M in Milestones Plus 22% Royalties Across Middle East and North Africa ? • Agreement with Roots Pharmaceutical includes up to $4M in upfront and early development payments, plus up to $255M in sales milestones. • Roots receives exclusive regional rights to OCU400 for retinitis pigmentosa, while Ocugen retains manufacturing and supply responsibilities. • Phase 3 liMeliGhT topline results expected in Q1 2027, followed by planned U.S. and European regulatory submissions. 14-OCT-2026 06:36 AM ET